GSK, Amgen and AstraZeneca released positive data supporting their rival drugs in a condition called chronic rhinosinusitis ...

Amgen and Ideaya Biosciences are winding down their cancer combination study, closing off one way the Big Biotech was looking to dial up the efficacy of its PRMT5 inhibitor AMG 193. The ...

A substantial insider sell was reported on February 7, by Nancy A Grygiel, SVP & CCO at Amgen AMGN, based on the recent SEC filing. What Happened: Grygiel's recent move involves selling 1,589 ...

With a market cap of $153.4 billion, Amgen Inc. (AMGN) is a global leader in biotechnology, focusing on innovative human therapeutics across various therapeutic areas including oncology ...

Biotechnology specialist Amgen (NASDAQ:AMGN) reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 4, that topped analysts' consensus estimates. Analysts estimated Q4 adjusted EPS ...

Amgen Inc.'s Q4 2024 earnings beat expectations, with 11% YoY revenue growth and 13% EPS increase, showcasing robust performance for the company's growth strategy. Amgen's diversified portfolio ...